PROFILPELAJAR.COM

Cyclofenil
Clinical data
Trade names	Sexovid, others
Other names	Cyclophenil; F-6066; H-3452; ICI-48213; bis(p-Acetoxyphenyl)-cyclohexylidenemethane
AHFS/Drugs.com	International Drug Names
Routes of; administration	By mouth
Drug class	Selective estrogen receptor modulator; Progonadotropin
ATC code	G03GB01 (WHO) ;
Pharmacokinetic data
Elimination half-life	18–29 hours
Identifiers
	IUPAC name [4-[(4-Acetoxyphenyl)-cyclohexylidene-methyl]phenyl] acetate;
CAS Number	2624-43-3;
PubChem CID	2898;
ChemSpider	2795;
UNII	J468V64WZ1;
KEGG	D01281;
ChEMBL	ChEMBL141305;
CompTox Dashboard (EPA)	DTXSID4022866 ;
ECHA InfoCard	100.018.264
Chemical and physical data
Formula	C23H24O4
Molar mass	364.441 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(Oc3ccc(C(/c1ccc(OC(=O)C)cc1)=C2\CCCCC2)cc3)C;

Cyclofenil, sold under the brand name Sexovid among others, is a selective estrogen receptor modulator (SERM) medication which is used as a gonadotropin stimulant or ovulation inducer and in menopausal hormone therapy in women.^[3]^[4]^[5]^[6] It is mostly no longer available.^[6] The medication is taken by mouth.^[7]^[8]^[9]

Side effects of cyclofenil include liver toxicity among others.^[10] It is a selective estrogen receptor modulator (SERM) and hence is a mixed agonist–antagonist of the estrogen receptor (ER), the biological target of estrogens like estradiol.^[8] It has antiestrogenic effects on the hypothalamic–pituitary–gonadal axis and hence can increase sex hormone production and stimulate ovulation.^[8]^[11]

Cyclofenil was introduced for medical use in 1970.^[12] It has been mostly discontinued, but remains available in a few countries, including Brazil, Italy, and Japan.^[6]^[13]^[3] It has been used as a doping agent by male athletes.^[8]

Medical use

Cyclofenil is used to treat menstrual disturbances and anovulatory infertility caused by insufficiency of the hypothalamic–pituitary–gonadal axis in women.^[3] It has also been used to treat menopausal symptoms.^[3] The medication is generally used at a dosage of 400 to 600 mg per day.^[3]^[8]^[9]

Available forms

Cyclofenil has been available in the form of 100, 200, and 400 mg oral tablets.^[8]

Non-medical use

Cyclofenil has been used by male athletes to increase testosterone levels.^[8] It is not effective for this purpose in women.^[8]

Contraindications

Cyclofenil is contraindicated during pregnancy and in those with severe liver disease and unexplained uterine bleeding.^[14]

Side effects

Cyclofenil is associated with a relatively high incidence of hepatotoxicity.^[10] Biochemical signs of undesirable liver changes have been observed in 35% or more of individuals and 1% of individuals experience overt hepatitis.^[10]

Pharmacology

Pharmacodynamics

Cyclofenil is a SERM, or a mixed agonist and antagonist of the estrogen receptors (ERs).^[8] It is described as a relatively weak/mild SERM.^[8] The medication is generally less effective than other SERMs.^[15] The medication is an "impeded estrogen" and is thought to work as a progonadotropin by blocking the actions of estrogens in the pituitary gland and hypothalamus, thereby disinhibiting release of the gonadotropins luteinizing hormone and follicle-stimulating hormone.^[11] In men, cyclofenil can increase testosterone levels due its progonadotropic effects.^[8]

Pharmacokinetics

In terms of distribution, cyclofenil acts both centrally and peripherally.^[15] The elimination half-life of cyclofenil after a single 200 mg dose is 18 to 29 hours.^[1]^[2]

Chemistry

Cyclofenil is a nonsteroidal SERM and is closely related structurally to triphenylethylene SERMs like clomifene and tamoxifen.^[9] It has been referred to as a diphenylethylene derivative, differing from triphenylethylenes only by the replacement of one of the phenyl rings with a cyclohexane ring.^[16]^[11]

History

Cyclofenil was first introduced for medical use in 1970 under the brand name Ondogyne in France.^[12] Subsequently, it was introduced throughout the world under a variety of other brand names, including its most well-known brand name Sexovid.^[12]

Society and culture

Generic names

Cyclofenil is the English generic name of the drug and its INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name, and BANTooltip British Approved Name.^[4]^[5]^[6]

Brand names

Cyclofenil has been marketed under a variety of brand names including Ciclifen, Fertodur, Gyneuro, Klofenil, Menoferil, Menopax, Neoclym, Oginex, Ondonid, Ondogyne, Rehibin, Sexadieno, Sexovar, and Sexovid.^[17]^[12]^[13]

Availability

Cyclofenil remains available today only in Brazil, Italy, and Japan.^[6]^[13]^[3] In the past, it has also been available in France, Germany, Mexico, Sweden, Switzerland, Turkey, and the United Kingdom.^[5]^[12]^[13]^[3]

Regulation

Cyclofenil is included on the World Anti-Doping Agency list of illegal doping agents in sport.^[18]^[19]

Research

Cyclofenil was investigated as a possible treatment for scleroderma in the 1980s, but was found to be ineffective.^[20] Later study of its efficacy in treating Raynaud's phenomenon in people with scleroderma also found no significant benefit.^[21]

References

^ ^a ^b Insler V, Lunenfeld B (January 1993). Infertility: Male and Female. Churchill Livingstone. p. 458. ISBN 978-0-443-04514-1.
^ ^a ^b Blankstein J, Mashiach S, Lunenfeld B (1 July 1986). Ovulation Induction and in Vitro Fertilization. Year Book Medical Publishers. p. 113. ISBN 978-0-8151-0871-9.
^ ^a ^b ^c ^d ^e ^f ^g Sweetman SC, ed. (2009). "Sex hormones and their modulators". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. p. 2088. ISBN 978-0-85369-840-1.
^ ^a ^b Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 329–. ISBN 978-1-4757-2085-3.
^ ^a ^b ^c Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 284–. ISBN 978-3-88763-075-1.
^ ^a ^b ^c ^d ^e "List of 7 Menopausal Disorders Medications Compared". Drugs.com.
^ Seyffart G (6 December 2012). "Cyclofenil". Drug Dosage in Renal Insufficiency. Springer Science & Business Media. pp. 166–. ISBN 978-94-011-3804-8.
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k von Deutsch DA, Abukhalaf IK, Socci RR (15 October 2003). "Anabolic Doping Agents". In Mozayani A, Raymon L (eds.). Handbook of Drug Interactions: A Clinical and Forensic Guide. Springer Science & Business Media. pp. 555–. ISBN 978-1-59259-654-6.
^ ^a ^b ^c Meniru GI, Craft IL (31 July 1997). "Ovarian stimulation for assisted reproduction technologies". In Meniru GI, Brinsden PR, Craft IL (eds.). A Handbook of Intrauterine Insemination. Cambridge University Press. pp. 58–59, 207. ISBN 978-0-521-58676-4.
^ ^a ^b ^c Zimmerman HJ, Ishak KG (6 December 2012). "Steroids and Other Hormones". In Cameron R, Feuer G, de la Iglesia F (eds.). Drug-Induced Hepatotoxicity. Springer Science & Business Media. pp. 565–. ISBN 978-3-642-61013-4.
^ ^a ^b ^c Bishop PM (22 October 2013). "Clinical Manifestations of Disorders of the Human Ovary". In Zuckerman S, Weir BJ (eds.). Physiology. Elsevier Science. pp. 209–. ISBN 978-1-4832-5975-8.
^ ^a ^b ^c ^d ^e William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia (3rd ed.). Elsevier. pp. 1162–. ISBN 978-0-8155-1856-3.
^ ^a ^b ^c ^d "IBM Watson Health Products". IBM Watson Health Products. Retrieved 2021-11-01.
^ Mutschler E, Derendorf H, Schäfer-Korting M, Elrod K, Estes KS (1995). "Ovaries". Drug Actions: Basic Principles and Therapeutic Aspects. CRC Press. pp. 294–. ISBN 978-0-8493-7774-7.
^ ^a ^b Tatford EP (6 December 2012). "Excessive Vaginal Bleeding". Problems in Gynaecology. Springer Science & Business Media. pp. 105–106. ISBN 978-94-009-4125-0.
^ Horsky J (6 December 2012). "Oestrogens". In Horsky J, Presl J (eds.). Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 92–. ISBN 978-94-009-8195-9.
^ Negwer M, Scharnow HG (2001). Organic-chemical drugs and their synonyms: (an international survey). Wiley-VCH. p. 2397. ISBN 978-3-527-30247-5.
^ Chester N (13 November 2014). "Hormone and metabolic modulators". In Mottram DR, Chester N (eds.). Drugs in Sport. Routledge. pp. 117–. ISBN 978-1-134-70800-0.
^ Ed The Emtree Editorial Team (1 January 2004). Doping Search Guide 2004: Over 10,000 Substance Names in Reference to the 2004 WADA (World Anti-Doping Agency) List of Prohibited Substances and Methods. Elsevier. p. 82. ISBN 978-0-444-51752-4.
^ Torres MA, Furst DE (February 1990). "Treatment of generalized systemic sclerosis". Rheum Dis Clin North Am. 16 (1): 217–41. doi:10.1016/S0889-857X(21)01050-4. PMID 2406809.
^ Pope J, Fenlon D, Thompson A, et al. (2000). Pope J (ed.). "Cyclofenil for Raynaud's phenomenon in progressive systemic sclerosis". Cochrane Database Syst Rev. 1998 (2): CD000955. doi:10.1002/14651858.CD000955. PMC 7032887. PMID 10796397.

[InslerLunenfeld1993-1] Insler V, Lunenfeld B (January 1993). Infertility: Male and Female. Churchill Livingstone. p. 458. ISBN 978-0-443-04514-1.

[BlanksteinMashiach1986-2] Blankstein J, Mashiach S, Lunenfeld B (1 July 1986). Ovulation Induction and in Vitro Fertilization. Year Book Medical Publishers. p. 113. ISBN 978-0-8151-0871-9.

[Martindale-3] ^ ^a ^b ^c ^d ^e ^f ^g Sweetman SC, ed. (2009). "Sex hormones and their modulators". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. p. 2088. ISBN 978-0-85369-840-1.

[Elks2014-4] Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 329–. ISBN 978-1-4757-2085-3.

[IndexNominum2000-5] Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 284–. ISBN 978-3-88763-075-1.

[Drugs.com-6] "List of 7 Menopausal Disorders Medications Compared". Drugs.com.

[Seyffart2012-7] Seyffart G (6 December 2012). "Cyclofenil". Drug Dosage in Renal Insufficiency. Springer Science & Business Media. pp. 166–. ISBN 978-94-011-3804-8.

[MozayaniRaymon2003-8] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k von Deutsch DA, Abukhalaf IK, Socci RR (15 October 2003). "Anabolic Doping Agents". In Mozayani A, Raymon L (eds.). Handbook of Drug Interactions: A Clinical and Forensic Guide. Springer Science & Business Media. pp. 555–. ISBN 978-1-59259-654-6.

[MeniruBrinsden1997-9] Meniru GI, Craft IL (31 July 1997). "Ovarian stimulation for assisted reproduction technologies". In Meniru GI, Brinsden PR, Craft IL (eds.). A Handbook of Intrauterine Insemination. Cambridge University Press. pp. 58–59, 207. ISBN 978-0-521-58676-4.

[CameronFeuer2012-10] Zimmerman HJ, Ishak KG (6 December 2012). "Steroids and Other Hormones". In Cameron R, Feuer G, de la Iglesia F (eds.). Drug-Induced Hepatotoxicity. Springer Science & Business Media. pp. 565–. ISBN 978-3-642-61013-4.

[ZuckermanWeir2013-11] Bishop PM (22 October 2013). "Clinical Manifestations of Disorders of the Human Ovary". In Zuckerman S, Weir BJ (eds.). Physiology. Elsevier Science. pp. 209–. ISBN 978-1-4832-5975-8.

[Publishing2013-12] William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia (3rd ed.). Elsevier. pp. 1162–. ISBN 978-0-8155-1856-3.

[Micromedex-13] "IBM Watson Health Products". IBM Watson Health Products. Retrieved 2021-11-01.

[MutschlerDerendorf1995-14] Mutschler E, Derendorf H, Schäfer-Korting M, Elrod K, Estes KS (1995). "Ovaries". Drug Actions: Basic Principles and Therapeutic Aspects. CRC Press. pp. 294–. ISBN 978-0-8493-7774-7.

[Tatford2012-15] Tatford EP (6 December 2012). "Excessive Vaginal Bleeding". Problems in Gynaecology. Springer Science & Business Media. pp. 105–106. ISBN 978-94-009-4125-0.

[HorskyPresl2012-16] Horsky J (6 December 2012). "Oestrogens". In Horsky J, Presl J (eds.). Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 92–. ISBN 978-94-009-8195-9.

[NegwerScharnow2001-17] Negwer M, Scharnow HG (2001). Organic-chemical drugs and their synonyms: (an international survey). Wiley-VCH. p. 2397. ISBN 978-3-527-30247-5.

[MottramChester2014-18] Chester N (13 November 2014). "Hormone and metabolic modulators". In Mottram DR, Chester N (eds.). Drugs in Sport. Routledge. pp. 117–. ISBN 978-1-134-70800-0.

[Team2004-19] Ed The Emtree Editorial Team (1 January 2004). Doping Search Guide 2004: Over 10,000 Substance Names in Reference to the 2004 WADA (World Anti-Doping Agency) List of Prohibited Substances and Methods. Elsevier. p. 82. ISBN 978-0-444-51752-4.

[pmid2406809-20] Torres MA, Furst DE (February 1990). "Treatment of generalized systemic sclerosis". Rheum Dis Clin North Am. 16 (1): 217–41. doi:10.1016/S0889-857X(21)01050-4. PMID 2406809.

[pmid10796397-21] Pope J, Fenlon D, Thompson A, et al. (2000). Pope J (ed.). "Cyclofenil for Raynaud's phenomenon in progressive systemic sclerosis". Cochrane Database Syst Rev. 1998 (2): CD000955. doi:10.1002/14651858.CD000955. PMC 7032887. PMID 10796397.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

[19]

[20]

[21]

PROFILPELAJAR.COM

Cyclofenil

Medical use

Available forms

Non-medical use

Contraindications

Side effects

Pharmacology

Pharmacodynamics

Pharmacokinetics

Chemistry

History

Society and culture

Generic names

Brand names

Availability

Regulation

Research

References

Read other articles:

Daftar Wakil Bupati Wakatobi

العلاقات الإكوادورية التشيكية

أوديسا (نيويورك)

مغن

Nicolaus Reusner

Game 6

Concours Eurovision de la chanson 1986

Blindspotting

Frank Sabichi

Ramesses IV

P-class Melbourne tram

Rome, Georgia

Toyota Motor East Japan

Zahra Eshraghi

Alan Duncan

United States–Colombia Free Trade Agreement

Gray Television

List of international cricket centuries by Sachin Tendulkar

مدرسة سانت إدموند

金源镇